RxFinder RxPBMPharmaBenefitsRxSaverRxNewsMedicalClaimRxInsiderClinicalRx
A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn (Rylaze)

Asparagine-specific Enzyme class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2021-06-30
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
—/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
—
Across all dosage forms in distribution.
Highest NADAC
—
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn used for?

Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn is a Asparagine-specific Enzyme medication tracked in Medicare Part D.

Sources: CMS Part D Spending CY24 · CMS NADAC weekly · FDA Orange Book
Is there a generic for Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn?

No. Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn is brand-only with no generic equivalents currently in market.

Sources: CMS Part D Spending CY24 · CMS NADAC weekly · FDA Orange Book
How much does my plan pay for Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn?

NADAC pricing data not currently available for this drug.

Sources: CMS Part D Spending CY24 · CMS NADAC weekly · FDA Orange Book
Is Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn on the FDA shortage list?

No. Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn is not currently on the FDA Drug Shortage Database.

Sources: CMS Part D Spending CY24 · CMS NADAC weekly · FDA Orange Book

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Related questions.

Q&A librarySourced · reviewed quarterly
pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?
Browse all canonical questions →

Same class. Different math.

Asparagine-specific Enzyme2 alternatives in D1
01
Calaspargase Pegol
 Brand: asparlas
—Lowest NADAC
0Generic mfrs
—CY24 Part D spend
Compare →
02
Pegaspargase
 Brand: ONCASPAR
—Lowest NADAC
0Generic mfrs
—CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.